SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project.

Garcia Quesada, M; Yang, Y; Bennett, JC; Hayford, K; Zeger, SL; Feikin, DR; Peterson, ME; Cohen, AL; Almeida, SCG; Ampofo, K; et al. Garcia Quesada, M; Yang, Y; Bennett, JC; Hayford, K; Zeger, SL; Feikin, DR; Peterson, ME; Cohen, AL; Almeida, SCG; Ampofo, K; Ang, M; Bar-Zeev, N; Bruce, MG; Camilli, R; Chanto Chacón, G; Ciruela, P; Cohen, C; Corcoran, M; Dagan, R; De Wals, P; Desmet, S; Diawara, I; Gierke, R; Guevara, M; Hammitt, LL; Hilty, M; Ho, P-L; Jayasinghe, S; Kleynhans, J; Kristinsson, KG; Ladhani, SN; McGeer, A; Mwenda, JM; Nuorti, JP; Oishi, K; Ricketson, LJ; Sanz, JC; Savrasova, L; Setchanova, LP; Smith, A; Valentiner-Branth, P; Valenzuela, MT; van der Linden, M; van Sorge, NM; Varon, E; Winje, BA; Yildirim, I; Zintgraff, J; Knoll, MD; The Pserenade Team (2021) Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project. Microorganisms, 9 (4). p. 738. ISSN 2076-2607 https://doi.org/10.3390/microorganisms9040738
SGUL Authors: Ladhani, Shamez Nizarali

[img] PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB)
[img] PDF (Supplementary material) Supporting information
Download (1MB)

Abstract

Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5-7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.

Item Type: Article
Additional Information: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Keywords: PCV impact, global, meta-analysis, pneumococcal meningitis, serotype distribution
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Microorganisms
ISSN: 2076-2607
Language: eng
Media of Output: Electronic
Related URLs:
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
001World Health Organizationhttp://dx.doi.org/10.13039/100004423
UL1 TR001863NCATS NIH HHSUNSPECIFIED
INV-010429Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
OPP1189065Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
URI: https://openaccess.sgul.ac.uk/id/eprint/117579
Publisher's version: https://doi.org/10.3390/microorganisms9040738

Actions (login required)

Edit Item Edit Item